Poseida Therapeutics 관리
관리 기준 확인 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Kristin Yarema
최고 경영자
US$2.6m
총 보상
| CEO 급여 비율 | 14.7% |
| CEO 임기 | less than a year |
| CEO 소유권 | n/a |
| 경영진 평균 재임 기간 | 2.8yrs |
| 이사회 평균 재임 기간 | 3.5yrs |
최근 관리 업데이트
Recent updates
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%
Oct 19
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Sep 30Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Sep 09Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09FDA lifts clinical hold on Poseida's prostate cancer cell therapy study
Nov 02CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$113m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$3m | US$381k | -US$123m |
보상 대 시장: Kristin 의 총 보상 ($USD 2.58M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.32M ).
보상과 수익: Kristin 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.
CEO
Kristin Yarema (53 yo)
less than a year
테뉴어
US$2,581,106
보상
Dr. Kristin Yarema Ph.D. is President & CEO of Poseida Therapeutics, Inc. from January 01, 2024 and serves as its Director since January 2024. Dr. Yarema, was the Chief Commercial Officer and Senior Vice P...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.8yrs | US$3.82m | 0.15% $ 449.7k | |
| President | less than a year | US$2.58m | 데이터 없음 | |
| Chief Financial Officer | 4.3yrs | 데이터 없음 | 0.073% $ 219.4k | |
| Chief Operations Officer | 2.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief People & Administration Officer | 5.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP of Investor Relations & Corporate Communications | less than a year | 데이터 없음 | 데이터 없음 | |
| General Counsel | 4.3yrs | US$978.34k | 0.040% $ 121.5k | |
| Chief Scientific Officer of Cell Therapy | 4.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Regulatory Affairs | 3.1yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Patent Counsel | 2.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Business Development | 2.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | less than a year | 데이터 없음 | 데이터 없음 |
2.8yrs
평균 재임 기간
57yo
평균 연령
경험이 풍부한 관리: PSTX 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.8yrs | US$3.82m | 0.15% $ 449.7k | |
| President | less than a year | US$2.58m | 데이터 없음 | |
| Lead Independent Director | 6.3yrs | US$175.11k | 0.040% $ 121.5k | |
| Chairman of Cell Therapy Scientific Advisory Board | 3.7yrs | 데이터 없음 | 데이터 없음 | |
| Chairman of Gene Therapy Scientific Advisory Board | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.8yrs | US$149.11k | 0.051% $ 152.4k | |
| Independent Director | 3.3yrs | US$155.28k | 0.040% $ 121.5k | |
| Independent Director | 2.5yrs | US$150.28k | 0.047% $ 141.7k | |
| Independent Director | 3.9yrs | US$140.11k | 0.040% $ 121.5k | |
| Member of Scientific Advisory Board | 3.5yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.5yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.5yrs | 데이터 없음 | 데이터 없음 |
3.5yrs
평균 재임 기간
66yo
평균 연령
경험이 풍부한 이사회: PSTX 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.